sunvozertinib · Dizal · NDA 219839
Zegfrovy
Earliest generic entry, as listed · earliest of 2 marketed strengths
28 Jan 2039
Blocked by patent: US 11007198, US 11504375, US 11896597.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11007198 | drug substance, drug product · sets the listed date | 28 Jan 2039 |
| US 11504375 | drug substance, drug product, use U-3220 · sets the listed date | 28 Jan 2039 |
| US 11896597 | drug substance, drug product, use U-3220 · sets the listed date | 28 Jan 2039 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 2 Jul 2030 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219839 · 001 · RLD | tablet, oral | 150MG | 28 Jan 2039 |
| 219839 · 002 · RLD | tablet, oral | 200MG | 28 Jan 2039 |